Do analysts rate NUWE or NDRA?

ENDRA Life Sciences has a consensus target price of $25.00, suggesting a potential upside of 396.03%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe ENDRA Life Sciences is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is NUWE or NDRA more profitable?

ENDRA Life Sciences has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. ENDRA Life Sciences' return on equity of -246.34% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -123.38% -623.14% -147.34% ENDRA Life Sciences N/A -246.34% -150.81%

Do analysts prefer NUWE or SONX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sonendo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, NUWE or SONX?

Nuwellis has higher earnings, but lower revenue than Sonendo. Sonendo is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuwellis $8.27M 0.27 -$17.52M -$132.59 N/A Sonendo $44.40M 0.14 -$60.92M -$71.12 N/A

Is NUWE or SONX more profitable?

Sonendo has a net margin of -92.74% compared to Nuwellis' net margin of -123.38%. Sonendo's return on equity of -184.01% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -123.38% -623.14% -147.34% Sonendo -92.74% -184.01% -68.60%

Do analysts rate NUWE or NVNO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Is NUWE or NVNO more profitable?

enVVeno Medical has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. enVVeno Medical's return on equity of -62.28% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -123.38% -623.14% -147.34% enVVeno Medical N/A -62.28% -56.83%

Do analysts rate INBS or NUWE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intelligent Bio Solutions 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate MBAI or NUWE?

MBody AI presently has a consensus target price of $10.00, suggesting a potential upside of 225.73%. Given MBody AI's stronger consensus rating and higher possible upside, equities research analysts clearly believe MBody AI is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBody AI 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MBAI or NUWE more profitable?

MBody AI has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. MBody AI's return on equity of 0.00% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets MBody AI N/A N/A N/A Nuwellis -123.38% -623.14% -147.34%

Does the media prefer MBAI or NUWE?

In the previous week, Nuwellis had 1 more articles in the media than MBody AI. MarketBeat recorded 4 mentions for Nuwellis and 3 mentions for MBody AI. Nuwellis' average media sentiment score of 0.74 beat MBody AI's score of 0.61 indicating that Nuwellis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBody AI 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuwellis 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nuwellis (NUWE) Competitors

$0.53 -0.09 (-14.65%)

Closing price 04:00 PM Eastern

Extended Trading

$0.56 +0.03 (+5.09%)

As of 06:31 PM Eastern

Compare

NUWE vs. NDRA, SONX, NVNO, INBS, and MBAI

Should you buy Nuwellis stock or one of its competitors? Nuwellis's main competitors and comparable companies include ENDRA Life Sciences (NDRA), Sonendo (SONX), enVVeno Medical (NVNO), Intelligent Bio Solutions (INBS), and MBody AI (MBAI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Nuwellis compare to ENDRA Life Sciences?

Nuwellis (NASDAQ:NUWE) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

ENDRA Life Sciences has a consensus target price of $25.00, suggesting a potential upside of 396.03%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe ENDRA Life Sciences is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ENDRA Life Sciences has lower revenue, but higher earnings than Nuwellis. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.27	-$17.52M	-$132.59	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$6.38	N/A

In the previous week, Nuwellis had 3 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 4 mentions for Nuwellis and 1 mentions for ENDRA Life Sciences. ENDRA Life Sciences' average media sentiment score of 1.79 beat Nuwellis' score of 0.74 indicating that ENDRA Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuwellis	Positive
ENDRA Life Sciences	Very Positive

ENDRA Life Sciences has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. ENDRA Life Sciences' return on equity of -246.34% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-123.38%	-623.14%	-147.34%
ENDRA Life Sciences	N/A	-246.34%	-150.81%

Nuwellis has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market.

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 1.6% of Nuwellis shares are held by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

ENDRA Life Sciences beats Nuwellis on 9 of the 14 factors compared between the two stocks.

How does Nuwellis compare to Sonendo?

Nuwellis (NASDAQ:NUWE) and Sonendo (NYSE:SONX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

Nuwellis has higher earnings, but lower revenue than Sonendo. Sonendo is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.27	-$17.52M	-$132.59	N/A
Sonendo	$44.40M	0.14	-$60.92M	-$71.12	N/A

In the previous week, Nuwellis had 4 more articles in the media than Sonendo. MarketBeat recorded 4 mentions for Nuwellis and 0 mentions for Sonendo. Nuwellis' average media sentiment score of 0.74 beat Sonendo's score of 0.00 indicating that Nuwellis is being referred to more favorably in the media.

Company	Overall Sentiment
Nuwellis	Positive
Sonendo	Neutral

Sonendo has a net margin of -92.74% compared to Nuwellis' net margin of -123.38%. Sonendo's return on equity of -184.01% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-123.38%	-623.14%	-147.34%
Sonendo	-92.74%	-184.01%	-68.60%

3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 28.7% of Sonendo shares are owned by institutional investors. 1.6% of Nuwellis shares are owned by company insiders. Comparatively, 7.9% of Sonendo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nuwellis has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Sonendo has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Sonendo beats Nuwellis on 8 of the 14 factors compared between the two stocks.

How does Nuwellis compare to enVVeno Medical?

Nuwellis (NASDAQ:NUWE) and enVVeno Medical (NASDAQ:NVNO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

Nuwellis has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, enVVeno Medical has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

enVVeno Medical has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. enVVeno Medical's return on equity of -62.28% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-123.38%	-623.14%	-147.34%
enVVeno Medical	N/A	-62.28%	-56.83%

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are held by institutional investors. 1.6% of Nuwellis shares are held by company insiders. Comparatively, 15.0% of enVVeno Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Nuwellis has higher revenue and earnings than enVVeno Medical. enVVeno Medical is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.27	-$17.52M	-$132.59	N/A
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A

In the previous week, Nuwellis had 3 more articles in the media than enVVeno Medical. MarketBeat recorded 4 mentions for Nuwellis and 1 mentions for enVVeno Medical. enVVeno Medical's average media sentiment score of 1.79 beat Nuwellis' score of 0.74 indicating that enVVeno Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuwellis	Positive
enVVeno Medical	Very Positive

Summary

enVVeno Medical beats Nuwellis on 10 of the 14 factors compared between the two stocks.

How does Nuwellis compare to Intelligent Bio Solutions?

Intelligent Bio Solutions (NASDAQ:INBS) and Nuwellis (NASDAQ:NUWE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Intelligent Bio Solutions has a beta of 4.31, meaning that its share price is 331% more volatile than the broader market. Comparatively, Nuwellis has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intelligent Bio Solutions	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

33.0% of Intelligent Bio Solutions shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 1.3% of Intelligent Bio Solutions shares are owned by insiders. Comparatively, 1.6% of Nuwellis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Nuwellis has a net margin of -123.38% compared to Intelligent Bio Solutions' net margin of -294.88%. Intelligent Bio Solutions' return on equity of -175.35% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intelligent Bio Solutions	-294.88%	-175.35%	-91.25%
Nuwellis	-123.38%	-623.14%	-147.34%

In the previous week, Nuwellis had 2 more articles in the media than Intelligent Bio Solutions. MarketBeat recorded 4 mentions for Nuwellis and 2 mentions for Intelligent Bio Solutions. Intelligent Bio Solutions' average media sentiment score of 1.45 beat Nuwellis' score of 0.74 indicating that Intelligent Bio Solutions is being referred to more favorably in the media.

Company	Overall Sentiment
Intelligent Bio Solutions	Positive
Nuwellis	Positive

Intelligent Bio Solutions has higher earnings, but lower revenue than Nuwellis. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intelligent Bio Solutions	$4.22M	1.16	-$12.43M	-$9.02	N/A
Nuwellis	$8.27M	0.27	-$17.52M	-$132.59	N/A

Summary

Intelligent Bio Solutions beats Nuwellis on 9 of the 14 factors compared between the two stocks.

How does Nuwellis compare to MBody AI?

MBody AI (NASDAQ:MBAI) and Nuwellis (NASDAQ:NUWE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

In the previous week, Nuwellis had 1 more articles in the media than MBody AI. MarketBeat recorded 4 mentions for Nuwellis and 3 mentions for MBody AI. Nuwellis' average media sentiment score of 0.74 beat MBody AI's score of 0.61 indicating that Nuwellis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBody AI	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuwellis	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

1.1% of MBody AI shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 0.5% of MBody AI shares are held by company insiders. Comparatively, 1.6% of Nuwellis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

MBody AI has higher earnings, but lower revenue than Nuwellis. MBody AI is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBody AI	N/A	N/A	$4.14M	-$7.42	N/A
Nuwellis	$8.27M	0.27	-$17.52M	-$132.59	N/A

MBody AI presently has a consensus target price of $10.00, suggesting a potential upside of 225.73%. Given MBody AI's stronger consensus rating and higher possible upside, equities research analysts clearly believe MBody AI is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBody AI	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

MBody AI has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. MBody AI's return on equity of 0.00% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBody AI	N/A	N/A	N/A
Nuwellis	-123.38%	-623.14%	-147.34%

MBody AI has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, Nuwellis has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Summary

MBody AI beats Nuwellis on 9 of the 14 factors compared between the two stocks.

Get Nuwellis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUWE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUWE vs. The Competition

Export

Metric	Nuwellis	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.93M	$5.56B	$7.28B	$12.93B
Dividend Yield	N/A	1.75%	2.51%	22.89%
P/E Ratio	0.00	25.42	275.31	25.30
Price / Sales	0.23	40.31	556.94	76.39
Price / Cash	N/A	32.25	77.16	53.04
Price / Book	0.01	5.72	10.51	5.92
Net Income	-$17.52M	$146.93M	$3.50B	$381.04M
7 Day Performance	-23.27%	-2.51%	-4.33%	-4.39%
1 Month Performance	-33.45%	-5.02%	-8.64%	-7.26%
1 Year Performance	-99.56%	0.44%	2.04%	-4.95%

Nuwellis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUWE Nuwellis	0.5271 of 5 stars	$0.53 -14.7%	N/A	-99.5%	$1.93M	$8.27M	N/A	38	Short Interest Increase
NDRA ENDRA Life Sciences	3.1997 of 5 stars	$6.06 +0.3%	$25.00 +312.5%	-37.9%	$9.06M	N/A	N/A	11
SONX Sonendo	N/A	$1.28 +28.0%	N/A	N/A	$6.11M	$44.40M	N/A	250	Gap Up
NVNO enVVeno Medical	1.5424 of 5 stars	$8.17 -0.4%	N/A	-69.3%	$5.70M	N/A	N/A	33	Gap Down
INBS Intelligent Bio Solutions	1.407 of 5 stars	$1.59 +0.6%	N/A	-86.2%	$5.24M	$4.22M	N/A	10	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NUWE) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuwellis (NUWE) Competitors

NUWE vs. NDRA, SONX, NVNO, INBS, and MBAI

How does Nuwellis compare to ENDRA Life Sciences?

Summary

How does Nuwellis compare to Sonendo?

Summary

How does Nuwellis compare to enVVeno Medical?

Summary

How does Nuwellis compare to Intelligent Bio Solutions?

Summary

How does Nuwellis compare to MBody AI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE vs. The Competition

Nuwellis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuwellis (NUWE) Competitors

NUWE vs. NDRA, SONX, NVNO, INBS, and MBAI

How does Nuwellis compare to ENDRA Life Sciences?

Do analysts rate NUWE or NDRA?

Which has stronger valuation & earnings, NUWE or NDRA?

Does the media refer more to NUWE or NDRA?

Is NUWE or NDRA more profitable?

Which has more volatility and risk, NUWE or NDRA?

Do institutionals and insiders have more ownership in NUWE or NDRA?

Summary

How does Nuwellis compare to Sonendo?

Which has better valuation and earnings, NUWE or SONX?

Does the media favor NUWE or SONX?

Is NUWE or SONX more profitable?

Do institutionals & insiders have more ownership in NUWE or SONX?

Which has more risk and volatility, NUWE or SONX?

Do analysts prefer NUWE or SONX?

Summary

How does Nuwellis compare to enVVeno Medical?

Which has more volatility and risk, NUWE or NVNO?

Do analysts rate NUWE or NVNO?

Is NUWE or NVNO more profitable?

Do institutionals and insiders believe in NUWE or NVNO?

Which has higher earnings and valuation, NUWE or NVNO?

Does the media favor NUWE or NVNO?

Summary

How does Nuwellis compare to Intelligent Bio Solutions?

Which has more risk and volatility, INBS or NUWE?

Do analysts rate INBS or NUWE?

Do insiders & institutionals hold more shares of INBS or NUWE?

Is INBS or NUWE more profitable?

Does the media refer more to INBS or NUWE?

Which has preferable earnings & valuation, INBS or NUWE?

Summary

How does Nuwellis compare to MBody AI?

Does the media prefer MBAI or NUWE?

Do insiders and institutionals hold more shares of MBAI or NUWE?

Which has preferable earnings & valuation, MBAI or NUWE?

Do analysts rate MBAI or NUWE?

Is MBAI or NUWE more profitable?

Which has more risk & volatility, MBAI or NUWE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE vs. The Competition

Nuwellis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools